Literature DB >> 15086182

Comparison of characteristics of recurrent esophageal varices after endoscopic ligation versus endoscopic ligation plus sclerotherapy.

Hiroshi Yoshida1, Takashi Tajiri, Yasuhiro Mamada, Nobuhiko Taniai, Atsushi Hirakata, Youichi Kawano, Yoshiaki Mizuguchi, Tetsuya Shimizu, Tsubasa Takahashi.   

Abstract

BACKGROUND/AIMS: The characteristics of recurrent esophageal varices after endoscopic variceal ligation (EVL) plus endoscopic injection sclerotherapy (EIS) versus EVL alone, including the number of additional treatments and patterns of recurrence have been compared.
METHODOLOGY: Thirty-four patients with cirrhosis and esophageal varices were treated by EVL alone (EVL group), and 46 patients were treated by EVL followed by extravariceal injection sclerotherapy (EVL+extraEIS group).
RESULTS: Fewer treatment sessions were needed (p<0.005), and more O-rings were required (p<0.0001) in the EVL group than in the EVL+extraEIS group. The 1- and 3-year cumulative recurrence rates were higher in the EVL group (81.3% and 93.8%) than in the EVL+extraEIS group (62.8% and 91.5%) (p<0.05). Endoscopic examination at first recurrence showed varices of a more severe form (p<0.001), but less frequently having the red color sign (p<0.0001), and intramucosal venous dilatation (p<0.0001) in the EVL group than in the EVL+extraEIS group. The number of rehospitalizations for additional treatment was lower (p<0.0001) and more patients could be managed with only endoscopic treatment for recurrent varices in the EVL group than in the EVL+extraEIS group (p<0.05).
CONCLUSIONS: Even if the overall rate of variceal recurrence was higher, fewer treatment sessions were needed, and the number of rehospitalizations for these additional treatments was lower in the EVL group than in the EVL+extraEIS group. Multiple sessions of EVL are an effective strategy for the treatment of esophageal varices.

Entities:  

Mesh:

Year:  2004        PMID: 15086182

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  5 in total

Review 1.  New methods for the management of gastric varices.

Authors:  Hiroshi Yoshida; Yasuhiro Mamada; Nobuhiko Taniai; Takashi Tajiri
Journal:  World J Gastroenterol       Date:  2006-10-07       Impact factor: 5.742

Review 2.  New methods for the management of esophageal varices.

Authors:  Hiroshi Yoshida; Yasuhiro Mamada; Nobuhiko Taniai; Takashi Tajiri
Journal:  World J Gastroenterol       Date:  2007-03-21       Impact factor: 5.742

3.  Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta-analysis.

Authors:  Danielle Roberts; Lawrence Mj Best; Suzanne C Freeman; Alex J Sutton; Nicola J Cooper; Sivapatham Arunan; Tanjia Begum; Norman R Williams; Dana Walshaw; Elisabeth Jane Milne; Maxine Tapp; Mario Csenar; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2021-04-10

4.  Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta-analysis.

Authors:  Maria Corina Plaz Torres; Lawrence Mj Best; Suzanne C Freeman; Danielle Roberts; Nicola J Cooper; Alex J Sutton; Davide Roccarina; Amine Benmassaoud; Laura Iogna Prat; Norman R Williams; Mario Csenar; Dominic Fritche; Tanjia Begum; Sivapatham Arunan; Maxine Tapp; Elisabeth Jane Milne; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2021-03-30

5.  Effect of dexmedetomidine in the prophylactic endoscopic injection sclerotherapy for oesophageal varices: a study protocol for prospective interventional study.

Authors:  Hiroki Nishikawa; Yoshinori Iwata; Akio Ishii; Hirayuki Enomoto; Yukihisa Yuri; Noriko Ishii; Yuho Miyamoto; Kunihiro Hasegawa; Chikage Nakano; Ryo Takata; Takashi Nishimura; Kazunori Yoh; Nobuhiro Aizawa; Yoshiyuki Sakai; Naoto Ikeda; Tomoyuki Takashima; Hiroko Iijima; Shuhei Nishiguchi
Journal:  BMJ Open Gastroenterol       Date:  2017-06-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.